Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial.
Mileshkin LR, Moore KN, Barnes EH, Gebski V, Narayan K, King MT, Bradshaw N, Lee YC, Diamante K, Fyles AW, Small W Jr, Gaffney DK, Khaw P, Brooks S, Thompson JS, Huh WK, Mathews CA, Buck M, Suder A, Lad TE, Barani IJ, Holschneider CH, Van Dyk S, Quinn M, Rischin D, Monk BJ, Stockler MR. Mileshkin LR, et al. Among authors: fyles aw. Lancet Oncol. 2023 May;24(5):468-482. doi: 10.1016/S1470-2045(23)00147-X. Epub 2023 Apr 17. Lancet Oncol. 2023. PMID: 37080223 Free PMC article. Clinical Trial.
Concurrent chemoradiation in advanced cervical cancer.
Thomas G, Dembo A, Fyles A, Gadalla T, Beale F, Bean H, Pringle J, Rawlings G, Bush R, Black B. Thomas G, et al. Gynecol Oncol. 1990 Sep;38(3):446-51. doi: 10.1016/0090-8258(90)90089-4. Gynecol Oncol. 1990. PMID: 2227560 Review.
Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer.
Lim K, Small W Jr, Portelance L, Creutzberg C, Jürgenliemk-Schulz IM, Mundt A, Mell LK, Mayr N, Viswanathan A, Jhingran A, Erickson B, De los Santos J, Gaffney D, Yashar C, Beriwal S, Wolfson A, Taylor A, Bosch W, El Naqa I, Fyles A; Gyn IMRT Consortium. Lim K, et al. Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):348-55. doi: 10.1016/j.ijrobp.2009.10.075. Epub 2010 May 14. Int J Radiat Oncol Biol Phys. 2011. PMID: 20472347
Variability in clinical target volume delineation for intensity modulated radiation therapy in 3 challenging cervix cancer scenarios.
Lim K, Erickson B, Jürgenliemk-Schulz IM, Gaffney D, Creutzberg CL, Viswanathan A, Portelance L, Beriwal S, Wolfson A, Bosch W, De Los Santos J, Yashar C, Jhingran A, Varia M, El Naqa I, King B, Fyles A. Lim K, et al. Pract Radiat Oncol. 2015 Nov-Dec;5(6):e557-65. doi: 10.1016/j.prro.2015.06.011. Epub 2015 Jul 2. Pract Radiat Oncol. 2015. PMID: 26432679 Free PMC article.
Consensus Recommendations for Radiation Therapy Contouring and Treatment of Vulvar Carcinoma.
Gaffney DK, King B, Viswanathan AN, Barkati M, Beriwal S, Eifel P, Erickson B, Fyles A, Goulart J, Harkenrider M, Jhingran A, Klopp A, Koh WJ, Lim K, Petersen I, Portelance L, Small W Jr, Stewart A, Wiebe E, Wolfson A, Yashar C, Bosch W. Gaffney DK, et al. Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1191-200. doi: 10.1016/j.ijrobp.2016.02.043. Epub 2016 Feb 21. Int J Radiat Oncol Biol Phys. 2016. PMID: 27130794 Free PMC article.
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Kitchener HC, Nijman HW, Kruitwagen RF, Nout RA, Verhoeven-Adema KW, Smit VT, Putter H, Creutzberg CL; PORTEC study group. de Boer SM, et al. Lancet Oncol. 2016 Aug;17(8):1114-1126. doi: 10.1016/S1470-2045(16)30120-6. Epub 2016 Jul 7. Lancet Oncol. 2016. PMID: 27397040 Free article. Clinical Trial.
Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer.
de Boer SM, Wortman BG, Bosse T, Powell ME, Singh N, Hollema H, Wilson G, Chowdhury MN, Mileshkin L, Pyman J, Katsaros D, Carinelli S, Fyles A, McLachlin CM, Haie-Meder C, Duvillard P, Nout RA, Verhoeven-Adema KW, Putter H, Creutzberg CL, Smit VTHBM; for PORTEC Study Group. de Boer SM, et al. Ann Oncol. 2018 Feb 1;29(2):424-430. doi: 10.1093/annonc/mdx753. Ann Oncol. 2018. PMID: 29190319 Free PMC article. Clinical Trial.
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group. de Boer SM, et al. Lancet Oncol. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Lancet Oncol. 2018. PMID: 29449189 Free PMC article. Clinical Trial.
208 results